Q3 2019 Investor Presentation

Track record of disciplined financial growth Revenue ($B) Adjusted EPS $1.6 10% CAGR $2.5 $2.42 9% CAGR $3.65 Quarterly dividend $0.25 8% CAGR $0.37 LTM 3Q14 LTM 3Q19 LTM 3Q14 LTM 3Q19 LTM 3Q14 LTM 3Q19 Fiscal Years ended June 30 ©2019 ResMed I Q3 2019 Investor Presentation | 40 ResMed

View entire presentation